Who
Kieran O'Kane
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Biodesix.
In numbers
- Trades disclosed
- 107
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $88K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2021
- Last trade
- 23 Feb 2026
- Last filed
- 23 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Feb 2026filed 23 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $6,835535 at $12.78 | filing |
| 23 Feb 2026filed 23 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $6,837535 at $12.78 | filing |
| 20 Feb 2026filed 23 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —1,469 | filing |
| 20 Feb 2026filed 23 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,469 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,469 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —1,469 | filing |
| 10 Feb 2026filed 11 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $5,889584 at $10.08 | filing |
| 10 Feb 2026filed 11 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $5,887584 at $10.08 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —1,600 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —73 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —73 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,527 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,527 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —1,600 | filing |
| 16 Jan 2026filed 20 Jan 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $2,428298 at $8.15 | filing |
| 16 Jan 2026filed 20 Jan 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Sold | $2,429298 at $8.15 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —805 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —805 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —805 at $0.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —805 | filing |
News
Biodesix Targets 2028 Availability for AI-Assisted Lung Nodule Imaging TestBDSX · econotimes.com · 19 Oct 2026Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging BiomarkersBDSX · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Kieran O'Kane; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.